key: cord-0704933-bu6v42xt
authors: Kerawala, Asad Ali; Das, Bhagwan; Solangi, Ahda
title: Mesenteric ischemia in COVID-19 patients: A review of current literature
date: 2021-06-26
journal: World J Clin Cases
DOI: 10.12998/wjcc.v9.i18.4700
sha: f24f580167dde11ced0a12031909bdcac1e8f2ec
doc_id: 704933
cord_uid: bu6v42xt

BACKGROUND: Coronavirus disease 2019 (COVID-19) virus has affected all the systems of the body, defying all impressions of it being a respiratory virus only. AIM: To see the association of mesenteric ischemia with COVID-19. METHODS: After initial screening and filtering of the titles on PubMed and Google Scholar, 124 articles were selected. Articles were read in full, and the references were skimmed for relevance. Twenty-six articles (case reports and case series) were found to eligible for inclusion. References of these 26 articles were checked for any additional cases. Two more publications were found, and a total of 28 articles (22 case reports and 6 case series) have been included for review in this manuscript. RESULTS: A total of 41 cases of acute mesenteric ischemia in COVID-19 patients have been reported in the literature since the outbreak of this pandemic. Most of them include patients with comorbidities. CONCLUSION: In conclusion, based on this literature review and precise published knowledge regarding acute mesenteric ischemia in patients with COVID-19, it is essential to understand its relevance in all patients with gastrointestinal symptoms. The threshold for the diagnostic investigations should also be kept low for the timely diagnosis and management of this disorder.

In December of 2019, the world witnessed the emergence of a novel virus that eventually gripped the whole world creating chaos and carnage. Wuhan, China was the first city to witness the fatal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1], which causes coronavirus disease 2019 (COVID- 19) . By March 11, 2020, the World Health Organization had already declared it a pandemic [2] As of December 15, 2020, over 70 million cases and 1.6 million deaths have been reported globally [3] , and the numbers keep rising. The United States, being the most affected, has more than 15468098 cases reported[3] and more than 293000 deaths. Adding to the misery is the fact that no single treatment has shown clinical benefit, and the drugs that have shown any benefit are still a point of major debate. A vaccine has recently been developed and approved for use by the Food and Drug Administration. However, the long-term effects and efficacy are still unknown. All the evidence about this unprecedented disease and its treatment is based on anecdotal events and opinions as there are no any previous experiences.

COVID -19 was initially thought to affect only the respiratory system, but other systemic manifestations were reported. There is a plethora of evidence suggesting a hypercoagulable state and prothrombotic tendency in patients suffering from COVID- 19[4,5] . Acute mesenteric ischemia (AMI) itself is a fatal disease. In combination with COVID-19, there is a high mortality. This manuscript is aimed at reviewing the medical literature for cases of AMI in COVID-19 patients.

A rapid systemic review of the medical literature was done for the eligible cases.

An extensive search was carried out using PubMed and Google Scholar using the keywords "mesenteric ischemia," "small bowel gangrene" and "COVID-19." Only the cases reported after January 2020 were searched. No language restriction was applied. A manual search of the bibliographies of the included cases was done to detect additional eligible cases.

The results from the mentioned search engines were filtered and screened by the title and the abstract. The articles of potential significance to our study were then assessed by full text. The inclusion criteria used were: (1) Case report/case series; (2) Patients with clinical suspicion, radiological or biochemical diagnosis of COVID-19; (3) Reported after January 2020; and (4) Underwent laparotomy or abdominal computed tomography to confirm the diagnosis of mesenteric ischemia.

The data extraction was performed by Kerawala AA and Das B. For all cases reported, the following parameters were recorded: country, date of publication, age and gender of the patient, comorbidities, clinical course, any complications, treatment given and eventual outcome.

The results of the extraction have been prepared and presented in a table form (Table 1 ) as well as narrated in text.

The initial search revealed 316 and 161 publications on PubMed and Google Scholar, respectively. After initial screening and filtering of the titles, 124 articles were selected. The full article was read, and the references were skimmed for relevance. Twenty-six articles (case reports and case series) were found to be eligible for inclusion. References of these 26 articles were checked for any additional cases. Two more publications were found. A total of 28 articles (22 case reports and 6 case series) have been included for review in this manuscript ( Figure 1 ).

A total of 41 cases of AMI in COVID-19 patients have been reported in the literature since the outbreak of this pandemic. The first case reported was on April 30 from Cremona, Italy by Beccara et al [6] . The rapid review and fast track publication by journals in the COVID-19 era led to overlap of many cases published online at the same time in the preproof version and the final manuscript published later. After thorough research, this was the first reported case in our opinion.

Out of these 41 cases, 27 (67%) were males, 10 (24%) were females, and demographics were not available for 4 (9%) patients. The median age of presentation was 59 years. The median age for males was 58.0 and for females was 61.5. The youngest case presented was of a 9-year-old girl from Algeria by Khesrani et al [7] . The oldest patients were 82-years-old and were from India and the United States.

France reported the most cases (n = 10) followed by Italy (n = 6), Turkey (n = 6), the United States (n = 5) and Spain (n = 4). Two cases were reported from Mexico. One case was reported from Iran, the United Kingdom, India, Algeria, Kuwait, Singapore, Brazil and the Netherlands each. The biggest case series was reported from Turkey (n = 5) [8] . Interestingly, no case has been reported from China, the country where the virus first emerged.

Reverse transcriptase polymerase chain reaction from the nasopharyngeal swab was the most frequently used test (n = 31) to confirm the diagnosis of COVID-19. Nine patients were diagnosed with COVID-19 on the presence of classical clinical symptoms and bilateral ground glass appearance on computed tomography chest, despite having a negative PCR from the nasal swab. One patient was diagnosed with COVID-19 after RNA detection by in situ hybridization from the necrotic bowel found on laparotomy.

Thirteen patients had no comorbidities or past medical history. Hypertension was the most common comorbidity present in 10 patients followed by obesity (n = 7) and diabetes mellitus (n = 6). The details have been presented in Table 1 .

Thirty-three patients underwent an exploratory laparotomy and resection of the gangrenous bowel segment after confirming the diagnosis of AMI. Four patients were treated conservatively with enoxaparin likely because the general condition of patient was not fit for anesthesia. One of these had a thrombus in the portal vein and superior mesenteric vein and was treated successfully without surgical intervention by thrombolytics [8] . No treatment details were available for 4 patients.

Fourteen (34%) patients were reported dead out of the published group. No information was available for 11 (27%) patients, and 16 (39%) patients were reported alive at the time of the publication of their case. However, most of the cases were published immediately after the presentation of the patient to the hospital and the cases reported a follow-up of 2-3 d only. Some cases reported the patient was still in the intensive care unit postoperatively. Hence, it is difficult to ascertain the true mortality rate of AMI in COVID-19 patients unless a complete follow-up of the patient is reported by the authors. Of those expired, 12 (86%) had undergone laparotomy and resection of the necrotic bowel and still succumbed to the disease. Two (14%) were treated conservatively with low molecular weight heparin. Of those reported alive, 14 (87%) patients underwent a laparotomy and resection of bowel. Two (13%) patients were treated conservatively. However, this was not statistically significant (95% confidence interval (CI): 0.1043 to 7.0432, P = 0.88) June 26, 2021 Volume 9 Issue 18

Out of the 14 expired, 10 (72%) had comorbid conditions and 4 (28%) did not have any. However statistical significance could not be ascertained without complete data on all the patients published. Again, no statistical significance was found (95%CI: 0.3633 to 5.9522, P = 0.58).

COVID-19 was initially thought to be a respiratory virus causing pneumonia and other respiratory complications only. However, throughout pandemic the world has witnessed it affecting almost every single body organ along with coagulopathy and AMI [9] [10] [11] .

AMI is a rare life-threatening abdominal emergency with a reported mortality around 60% to 80% [12] . It requires a prompt diagnosis and imaging in highly suspicious patients. Because of the evolving nature of SARS-CoV-2, the exact pathogenesis leading to thrombosis and AMI after this infection remains ambiguous. There are different hypotheses behind this deadly manifestation. Taking them all into account, it appears that patients with COVID-19 fulfil the classic Virchow's triad required for thrombosis.

Endothelial injury is the first element of Virchow's triad and has been reported to be caused by direct invasion by SARS-CoV-2 via its binding with angiotensin-converting enzyme 2 receptors expressed on vascular endothelium [13, 14] . In addition to this, immune complex-mediated vasculitis has also been postulated as one of the mechanisms behind vascular damage in COVID- 19[15] . Both of these in combination can cause endothelial dysfunction and predispose a patient to thrombus formation.

Hypercoagulpopoathy, the second element of Virchow's triad, is also seen in this infection secondary to the number of pathological changes in the vascular prothrombotic factors, like elevated fibrinogen and factor VIII, hyperviscosity, neutrophil extracellular traps and circulating prothrombotic microparticles [16] [17] [18] . This hypercoagulability state has been documented via thromboelastography in COVID-19 patients admitted in intensive care units [17] .

Stasis, the final element of Virchow's triad, can be expected in all critically ill patients because of isolation in a confined area, prolonged bed rest, immobilization in the intensive care unit and possible limitations to physiotherapy.

In addition to the above mechanisms, it has also been postulated that COVID-19 can cause direct damage to the bowel via binding with angiotensin-converting enzyme 2 receptors expressed on enterocytes [19, 20] . Lastly, hemodynamic instability in severe COVID-19 infection leading to hypotension and shock can be a possible mechanism of nonocclusive mesenteric ischemia seen in these patients.

Due to the poor prognosis of both severe COVID-19 infection and AMI, AMI should be suspected in all patients who present with nausea, vomiting, diarrhea, abdominal pain and abdominal distension or develop these symptoms during hospitalization. As inflammatory and coagulation profiles can be deranged in COVID-19 infection itself, blood tests will not aid in the diagnosis of AMI in these patients. Computed tomography angiography is the modality of choice for the diagnosis of AMI along with clinical correlation.

Preliminary data from a few reports have pointed towards in situ thrombosis of small vasculature as evidence for bowel necrosis with thrombosis in the submucosal arterioles[21], but new cases are being reported with involvement and complete occlusion of large vessels as well. Because of the paucity of data, exact incidence, pathogenesis and outcome of these patients is not known.

From available data, we have concluded that it is more commonly reported in males, and hypertension is found to be the most common comorbidity along with other metabolic syndromes entities, like obesity and dysglycemia. Most patients (80%) underwent laparotomy and bowel resection. A few patients were managed conservatively with anticoagulation and thrombolytics, mostly due to being unfit for surgery. True outcome data of AMI in COVID-19 patients is also difficult to report from this review as complete follow-up and the current status of many patients has not been reported. This is a limitation of our study.

In conclusion, based on this literature review of published reports regarding AMI in patients with COVID-19, it is essential to understand the relevance of AMI in all

Type 3 hypersensitivity in COVID-19 vasculitis

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

Acute Mesenteric Ischemia in Severe Coronavirus-19 (COVID-19): Possible Mechanisms and Diagnostic Pathway

Evidence for Gastrointestinal Infection of SARS-CoV-2

Abdominal Imaging Findings in COVID-19: Preliminary Observations

Small bowel ischemia and SARS-CoV-2 infection: an underdiagnosed distinct clinical entity

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Bowel ischemia in a suspected coronavirus disease (COVID-19) patient

Systemic arterial thrombosis and acute mesenteric ischemia in a patient with COVID-19

Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

Acute intestinal ischemia in a patient with COVID-19

SARS-CoV-2-related Hypercoagulable State Leading to Ischemic Enteritis Secondary to Superior Mesenteric Artery Thrombosis

Coagulopathy and mesenteric ischaemia in severe SARS-CoV-2 infection

Superior Mesenteric Artery Thrombosis and Acute Intestinal Ischemia as a Consequence of COVID-19 Infection

Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia

Espín-Basany E. Incidence, features, outcome and impact on health system of de-novo abdominal surgical diseases in patients admitted with COVID-19

Abdominal Visceral Infarction in 3 Patients with COVID-19

Acute Mesenteric Ischemia in a Patient with COVID-19: A Case Report

Unusual arterial thrombotic events in Covid-19 patients

Acute Intestinal Ischemia in a Patient with COVID-19 Infection

Severe ischemic complications in Covid-19-A case series

Arterial thrombotic complications in COVID-19 patients

Acute mesenteric thrombosis in two patients with COVID-19. Two cases report and literature review

Intestinal ischemia in the COVID-19 era

Superior Mesenteric Artery Thrombosis in a Patient with COVID-19: A Unique Presentation

Superior Mesenteric Artery Thrombosis in COVID-19 Pneumonia: an Underestimated Diagnosis-First Case Report in Asia